Osteoporosis in men: Pathophysiology and treatment

Current Rheumatology Reports

Volumn 9, Issue 1, 2007, Pages 71-77

  Gennari, Luigi ^b   Bilezikian, John P ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TESTOSTERONE; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ANDROGEN THERAPY; BONE DENSITY; BONE FRAGILITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DNA POLYMORPHISM; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; FRAGILITY FRACTURE; FUNCTION TEST; HORMONE SYNTHESIS; HUMAN; HYPOGONADISM; LABORATORY TEST; MONOTHERAPY; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; POPULATION RESEARCH; REVIEW; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

BONE DENSITY; BONE RESORPTION; HUMANS; MALE; OSTEOPOROSIS; RISK FACTORS;

EID: 34249278858     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0025-y     Document Type: Review

References (51)

1. Cummings SR, Melton LJ: Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359:1761-1767.
2. Center JR, Nguyen TV, Schneider D, et al.: Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999, 353:878-882.
3. • Cummings SR, Cawthon PM, Ensrud KE, et al.: BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res 2006, 21:1550-1556. A large prospective study indicating that the relationship between hip BMD and hip fracture risk in men is stronger than that observed in women.
4. Melton LJ: Epidemiology of fractures. In Osteoporosis: Etiology, Diagnosis and Management, 2nd edn. Edited by Riggs BL, Melton LJ. Philadelphia: Lippincott-Raven Publishers; 1995:225-247.
5. • Seeman E, Bianchi G, Khosla S, et al.: Bone fragility in men - where are we? Osteoporos Int 2006, 17:1577-1583. Review about recent advances and future challenges related to several aspects of the epidemiology, pathogenesis, and treatment of male osteoporosis.
6. •• Seeman E, Delmas PD: Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250-2261. A concise but complete review summarizing recent advances in the structural bases of bone fragility.
7. Riggs BL, Melton LJ 3rd, Robb RA, et al.: A population-based study of age and sex differences in bone volumetric density, size, geometry and structure at different skeletal sites. J Bone Miner Res 2004, 19:1945-1954.
8. Chavassieux P, Meunier PJ: Histomorphometric approach of bone loss in men. Calcif Tissue Int 2001, 69:209-213.
9. Khosla S: Idiopathic osteoporosis - is the osteoblast to blame? [editorial] J Clin Endocrinol Metab 1997, 82:2792-2794.
10. Bilezikian JP: Osteoporosis in men. J Clin Endocrinol Metab 1999, 84:3431-3434.
11. Pernow Y, Granberg B, Saaf M, Weidenhielm L: Osteoblast dysfunction in male idiopathic osteoporosis. Calcif Tissue Int 2006, 78:90-97.
12. Perry HM 3rd, Fallon MD, Bergfeld M, et al.: Osteoporosis in young men. Arch Intern Med 1982, 142:1295-1298.
13. Seeman E, Melton LJ 3rd, O'Fallon WM, Riggs BL: Risk factors for spinal osteoporosis in men. Am J Med 1983, 75:977-982.
14. Cauley JA, Fullman RL, Stone KL, et al.: Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 2005, 16:1525-1537.
15. Looker AC, Orwoll ES, Johnston CC, et al.: Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 1997, 12:1761-1768.
16. Gennari L, Brandi ML: Genetics of male osteoporosis. Calcif Tissue Int 2001, 69:200-204.
17. Eisman JA: Genetics of osteoporosis. Endocr Rev 1999, 20:788-804.
18. Gennari L, Masi L, Merlotti D, et al.: A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab 2004, 89:2803-2810.
19. Van Pottelbergh I, Goemaere S, Kaufman JM: Bioavailable estradiol and aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab 2003, 88:3075-3081.
20. Ferrari SL, Deutsch S, Baudoin C, et al.: LRP5 gene polymorphisms and idiopathic osteoporosis in men. Bone 2005, 37:770-775.
21. Rosen CJ, Kurland ES, Vereault D, et al.: An association between serum IGF-1 and a simple sequence repeat in the IGF-1 gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998, 83:2286-2290.
22. Lamberts SW, van den Beld AW, van der Lely A: The endocrinology of aging. Science 1997, 278:419-424.
23. Gray A, Feldman HA, McKinlay JB, Longcope C: Age, disease and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging study. J Clin Endocrinol Metab 1991, 73:1016-1025.
24. Orwoll E, Lambert LC, Marshall LM, et al.: Testosterone and estradiol among older men. J Clin Endocrinol Metab 2006, 91:1336-1344.
25. Khosla S, Melton LJ 3rd, Riggs BL: Clinical review 144: Estrogen and the male skeleton. J Clin Endocrinol Metab 2002, 87:1443-1450.
26. Slemenda CW, Longcope C, Zhou L, et al.: Sex steroids and bone mass in older men: positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997, 100:1755-1759.
27. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM: Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J. Clin Endocrinol Metab 2001, 86:3555-3561.
28. Gennari L, Merlotti D, Martini G, et al.: Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 2003, 88:5327-5333.
29. Szulc P, Munoz F, Claustrat B, et al.: Bioavailable estradiol may be an important determinant of osteoporosis in men. The MINOS Study. J Clin Endocrinol Metab 2001, 86:192-199.
30. Khosla S, Melton LJ 3rd, Robb RA, et al.: Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. J Bone Miner Res 2005, 20:730-740.
31. •• Gennari L, Nuti R, Bilezikian JP: Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab 2004, 89:5898-5907. Overview of the clinical and experimental aspects of aromatase, aromatase gene polymorphisms, and variations in aromatase efficiency in male skeletal homeostasis.
32. Ensrud KE, Lewis CE, Lambert LC, et al.: Endogenous sex steroids, weight change and rates of hip bone loss in older men: the MrOS study. Osteoporos Int 2006, 17:1329-1336.
33. Crave JC, Lejeune H, Brebant C, et al.: Differential effects of insulin-like growth factor I on the production of plasma steroid-binding globulins by human hepatoblastoma-derived (HepG2) cells. J Clin Endocrinol Metab 1995, 80:1283-1289.
34. Kurland ES, Rosen CJ, Cosman F, et al.: Insulin-like growth factor-1 men with idiopathic osteoporosis. J Clin Endocrinol Metab 1997, 82:2799-2805.
35. Kurland ES, Chan FK, Rosen CJ, Bilezikian JP: Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-1. J Clin Endocrinol Metab 1998, 83:2576-2579.
36. Rosen CJ, Kurland ES, Vereault D, et al.: An association between serum IGF-1 and a simple sequence repeat in the IGF-1 gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998, 83:2286-2290.
37. •• Khosla S, Melton LJ 3rd, Achenbach SJ, et al.: Hormonal and biochemical determinants of trabecular microstructure at the ultradistal radius in women and men. J Clin Endocrinol Metab 2006, 91:885-891. A analysis of the hormonal determinants of bone microarchitecture and gender-related differences.
38. Boullion R, Bex M, Vanderschueren D, Boonen S: Estrogens are essential for male pubertal periosteal bone expansion. J Clin Endocrinol Metab 2004, 89:6025-6029.
39. Kousteni S, Chen JR, Bellido T, et al.: Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 2002, 298:843-846.
40. Lewiecki EM, Watts NB, McClung MR, et al.: Official positions of the International Society for Clinical Densitometry. J Clin Endocrinol Metab 2004, 89:3651-3655.
41. Kiebzak GM, Beinart GA, Perser K, et al.: Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002, 162:2217-2222.
42. Feldstein AC, Nichols G, Orwoll E, et al.: The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int 2005, 16:953-962.
43. • Orwoll ES: Treatment of osteoporosis in men [review]. Calcif Tissue Int 2004, 75:114-119. Review of different treatment options for osteoporosis in men.
44. Orwoll E, Ettinger M, Weiss S, et al.: Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343:604-610.
45. Ringe ID, Faber H, Dorst A: Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 2001, 86:5252-5255.
46. Hodsman AB, Bauer DC, Dempster DW, et al.: Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005, 26:688-703.
47. Kurland ES, Cosman F, McMahon DJ, et al.: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85:3069-3076.
48. Kaufman JM, Orwoll E, Goemaere S, et al.: Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005, 16:510-516.
49. Bilezikian JP, Rubin MR: Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis. Curr Osteoporos Rep 2006, 4:5-13.
50. Tracz MJ, Sideras K, Bolona ER, et al.: Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006, 91:2011-2016.
51. Gennari L, Nuti R, Bilezikian JP: Estrogen in men: effects on bone accrual, maintenance and prevention of bone loss. Exp Rev Endocrinol Metab 2006, 1:281-295.